Guardant Health (NASDAQ:GH) Coverage Initiated by Analysts at Craig Hallum

Analysts at Craig Hallum assumed coverage on shares of Guardant Health (NASDAQ:GH) in a research report issued to clients and investors on Wednesday, StockNewsAPI reports. The firm set a “buy” rating and a $28.00 price target on the stock. Craig Hallum’s price objective suggests a potential upside of 56.34% from the company’s current price.

A number of other equities research analysts have also recently commented on GH. Canaccord Genuity Group reduced their price target on shares of Guardant Health from $50.00 to $45.00 and set a “buy” rating for the company in a report on Friday, February 23rd. JPMorgan Chase & Co. reduced their price objective on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Piper Sandler reduced their price objective on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating for the company in a report on Monday, February 26th. Guggenheim reiterated a “neutral” rating on shares of Guardant Health in a report on Friday, April 5th. Finally, The Goldman Sachs Group reduced their price objective on shares of Guardant Health from $32.00 to $28.00 and set a “buy” rating for the company in a report on Monday, April 15th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.27.

Guardant Health Trading Up 3.3 %

NASDAQ GH traded up $0.57 during mid-day trading on Wednesday, reaching $17.91. 281,316 shares of the stock were exchanged, compared to its average volume of 1,874,299. Guardant Health has a one year low of $15.81 and a one year high of $41.06. The stock has a 50 day simple moving average of $19.10 and a 200-day simple moving average of $23.11. The stock has a market cap of $2.18 billion, a P/E ratio of -4.17 and a beta of 0.87. The company has a debt-to-equity ratio of 7.18, a current ratio of 6.54 and a quick ratio of 6.24.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.65). The company had revenue of $155.05 million during the quarter, compared to analyst estimates of $151.71 million. Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. On average, analysts anticipate that Guardant Health will post -3.49 EPS for the current year.

Insiders Place Their Bets

In other Guardant Health news, insider Kumud Kalia purchased 2,187 shares of the stock in a transaction dated Monday, March 18th. The shares were bought at an average price of $17.82 per share, with a total value of $38,972.34. Following the completion of the transaction, the insider now directly owns 12,722 shares in the company, valued at approximately $226,706.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 6.20% of the company’s stock.

Institutional Trading of Guardant Health

Several hedge funds and other institutional investors have recently modified their holdings of GH. CWM LLC grew its stake in Guardant Health by 137.1% during the third quarter. CWM LLC now owns 984 shares of the company’s stock valued at $29,000 after acquiring an additional 569 shares in the last quarter. BluePath Capital Management LLC purchased a new position in Guardant Health during the third quarter valued at approximately $35,000. Headlands Technologies LLC grew its stake in Guardant Health by 362.3% during the fourth quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock valued at $64,000 after acquiring an additional 1,844 shares in the last quarter. Van ECK Associates Corp grew its stake in Guardant Health by 29.4% during the fourth quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock valued at $73,000 after acquiring an additional 614 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in Guardant Health by 26.1% during the third quarter. Nisa Investment Advisors LLC now owns 3,450 shares of the company’s stock valued at $102,000 after acquiring an additional 713 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.